DelveInsight’s Oncolytic Virus Cancer Therapy Pipeline Insights report provides a comprehensive outlook of the pipeline therapies in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Oncolytic Virus Cancer Therapy domain.
The ‘Oncolytic Virus Cancer Therapy Pipeline Analysis – 2021’ report provides a 360-degree view of the therapeutics environment for Oncolytic Virus Cancer Therapy emerging therapies by development point, product type, route of administration, molecule type, and MOA.
The Oncolytic Virus Cancer Therapy pipeline report lays down the business opportunities, threats, future collaborations, strong competitors, and growth strategies.
Some of the key highlights from the Oncolytic Virus Cancer Therapy Pipeline Report:
- 45+ key pharma players are proactively working to advance the Oncolytic Virus Cancer Therapy Pipeline.
- Over 85+ Oncolytic Virus Cancer Therapy pipeline therapies are under different stages of development, and their expected approval in the Oncolytic Virus Cancer Therapy market shall uplift the market revenue significantly.
- RIGVIR, a nonpathogenic enteric cytopathic human orphan virus, was approved in Latvia to treat melanoma.
- In June 2020, CG Oncology initiated a trial entitled “A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)”.
- In December 2020, CG Oncology initiated a Phase II trial entitled “Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)”.
- Key pipeline therapies involved in Oncolytic Virus Cancer Therapy includes Oncology, Targovax, and others.
Request for Sample @ Oncolytic Virus Cancer Therapy Pipeline Insights and Outlook
Oncolytic virus (OV) cancer therapies are the virus-based therapeutic strategies that infect and destroy cancer cells and act as an in situ cancer vaccine by releasing tumour-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumour cells while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumour immune responses. The anti-tumour efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.
Oncolytic Virus Cancer Therapy Pipeline Analysis: Drug Profile
CG0070: CG Oncology
CG0070 is investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 first replicates inside the tumour’s cells, causing tumour cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumour-derived antigens, along with GM-CSF, that can stimulate a systemic antitumor immune response that involves the body’s white blood cells. CG0070 is in development for various solid tumour types to be used alone or with immune checkpoint modulators.
ONCOS-102: Targovax
ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 had received Fast-Track designation in malignant pleural mesothelioma from the US FDA.
Dive deeper to know more @ Oncolytic Virus Cancer Therapy Therapeutics and Drugs Pipeline
Key Pipeline Therapies along with Companies
- CG0070: CG Oncology
- ONCOS-102: Targovax
Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- By Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
- Targets:
- Protease
- Immunomodulatory
- Multiple Kinase Inhibitor
- By Mechanism of Action
- Cell death stimulants
Got queries? Reach out for more information @ Oncolytic Virus Cancer Therapy Drug Pipeline Assessment
Scope of the Report
- Coverage: Global
- Key Market Players: CG0070, ONCOS-102, among others.
- Key Pipeline Therapies: CG Oncology, Targovax, among others.
Table of Contents:
| 1. | Report Introduction |
| 2. | Oncolytic Virus Cancer Therapy |
| 3. | Oncolytic Virus Cancer Therapy Current Treatment Patterns |
| 4. | Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective |
| 5. | Therapeutic Assessment |
| 6. | Oncolytic Virus Cancer Therapy Late Stage Products (Phase-III) |
| 7. | Oncolytic Virus Cancer Therapy Mid Stage Products (Phase-II) |
| 8. | Early Stage Oncolytic Virus Cancer Therapy Products (Phase-I) |
| 9. | Oncolytic Virus Cancer Therapy Preclinical Products and Discovery Stage Products |
| 10. | Inactive Products |
| 11. | Dormant Products |
| 12. | Oncolytic Virus Cancer Therapy Discontinued Products |
| 13. | Oncolytic Virus Cancer Therapy Product Profiles |
| 14. | Oncolytic Virus Cancer Therapy Key Companies |
| 15. | Oncolytic Virus Cancer Therapy Key Products |
| 16. | Dormant and Discontinued Products |
| 17. | Oncolytic Virus Cancer Therapy Unmet Needs |
| 18. | Oncolytic Virus Cancer Therapy Future Perspectives |
| 19. | Oncolytic Virus Cancer Therapy Analyst Review |
| 20. | Appendix |
| 21. | Report Methodology |
Know more of what’s covered in the Oncolytic Virus Cancer Therapy Pipeline Assessment report
Key Questions Answered in the Oncolytic Virus Cancer Therapy Report
- What are the current options for Oncolytic Virus Cancer Therapy treatment?
- How many companies are developing therapies for the treatment of Oncolytic Virus Cancer Therapy?
- What are the principal medicines developed by these companies in the industry?
- How many therapies are set by each company for the treatment of Oncolytic Virus Cancer Therapy?
- How many emerging therapies are in the early-stage, mid-stage, and late-stage of development to treat Oncolytic Virus Cancer Therapy?
- Out of total pipeline products, how many medicines are given as a monotherapy and in combination with other drugs?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Oncolytic Virus Cancer Therapy market?
Request for a Webex demo @ Oncolytic Virus Cancer Therapy Drug Pipeline and get a walk-through of our report
Related Reports
Natural Killer Cell Therapies – Competitive Landscape, Technology and Pipeline Analysis, 2021
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Abivax, Affimed Therapeutics, Altor Bioscience Corporation, Ambicion, Apceth Biopharma, Bellicum Pharmaceuticals, Biothera Pharmaceuticals, Bright Path Biotherapeutics, Bristol-Myers Squibb and several others.
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Boston Scientific Corporation, Medtronic, Medico S.p. A, Microport Scientific Corporation, Biotronik, EBR Systems,Inc, Abbott and several others.
Radiologic Cancer Therapy – Market Insights, Competitive Landscape and Market Forecast–2026
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Accuray, Inc., Nordion Inc., Varian Medical Systems, IsoRay, Inc., Ion Beam Applications SA, Elekta AB, C.R. Bard,Inc., Mallinckrodt Public Ltd., Mevion Medical Systems and several others.
Cancer Therapy Related Diarrhea – Pipeline Insights, 2021
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Napo Pharmaceuticals and several others.
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as BioMarin Pharmaceutical, Pfizer, Spark Therapeutics, uniQure/CSL Behring, NightstaRx Ltd, a Biogen Company, MeiraGTx, Neurocrine Biosciences/ Voyager Therapeutics, Sangamo Therapeutics, Freeline Therapeutics, Asklepios Biopharmaceutical (Actus Therapeutics) and several others.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as NOVARTIS, Miltenyi Biotec B.V. & Co. KG, Precision BioSciences, Autolus Limited and several others.
CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Bluebird bio/Celgene, Janssen Research & Development, Poseida Therapeutics, MolMed S.p.A., Celgene Corporation, Cartesian Therapeutics, CARsgen Therapeutics, Precision BioSciences and several others.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) – Market Insights and Market Forecast-2030
Get comprehensive historical and forecast analysis of Hemophilia B Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novartis, Gilead Sciences and several others.
Related Blog:
Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’?
Navigating Through the Treatment Market Landscape of Head and Neck Cancers
Get in touch with our Business executive for Pharma and Healthcare
Market Assessment and Consulting
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences providing comprehensive end-to-end solutions to improve performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
The post Oncolytic Virus Cancer Therapy Pipeline Analysis: 85+ Key Pipeline Therapies and 45+ Key Pharma Competitors to Look Out for in the Oncolytic Virus Cancer Therapy Pipeline Landscape appeared first on Financial Market Brief.
